New potential vaccine and treatment for Alzheimer’s enters the human trial phase
According to top-researchers from the University of Southern California, the best approach for finding a solution in order to help people affected by Alzheimer’s disease is to intensively focus on prevention.
As the disease is considered to be the sixth-leading cause of death in the United States and currently affects 47 million patients on a global level, scientists are tackling a vaccine and a new oral treatment in the attempt of preventing or delaying AD symptoms.
The challenge comes in finding a way to treat people that carry two copies of the APOE4 gene (apolipoprotein e4), the gene that is held responsible for more than half of the AD cases. The gene can be inherited from either one of both parents.
Participants to the clinical trials must have two copies of APOE4, from both parents, in order to qualify as admitted. It is considered that if scientists can find a vaccine or a treatment covering patients with two copies of APOE4, than the cure can be applied on other high-risk AD groups.
The treatment will be focusing on finding a way to prevent amyloid plaques to develop or to progress. Subjects participating in the study will be assigned a a vaccine or trial medication or the placebo corespondent of each one for a period of five to eight years.
According to the author of the study, if the research will be successful, the quality of the lives of people affected by the illness would be considerably improved, while the global incidence of AD would drop by half.